The firm is a corporate venture capital arm of a leading healthcare and diagnostics company based in Asia. The firm focuses on investing in later-stage life sciences and healthcare companies, typically from growth-stage financings through post-IPO opportunities. The firm generally makes investments below $10M per company and maintains a selective investment strategy. The firm evaluates opportunities globally and leverages the expertise, industry relationships, and commercial infrastructure of its parent organization to support portfolio companies.
The firm primarily focuses on therapeutics and diagnostics, while remaining open to select medical device and digital health opportunities. Within therapeutics, the firm is most interested in programs ranging from mid- to late-stage clinical development through commercial-stage assets. Areas of interest include cardiovascular diseases, respiratory diseases, oncology, autoimmune disorders, urology, and central nervous system disorders. Within in vitro diagnostics, the firm is open to a broad range of technologies spanning development-stage through clinical and commercial applications.
From a company and management team perspective, the firm seeks technologies with strong scientific foundations, clear commercial potential, and a high likelihood of successfully navigating regulatory approval pathways. As a strategic investor, the firm prioritizes opportunities that demonstrate meaningful differentiation and long-term market potential.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment